XNYS
BLCO
Market cap4.06bUSD
May 02, Last price
11.50USD
1D
-0.78%
1Q
-33.72%
IPO
-36.11%
Name
Bausch + Lomb Corp
Chart & Performance
P/E
—
P/S
0.85
EPS
—
Div Yield, %
—
Shrs. gr., 5y
0.10%
Rev. gr., 5y
4.79%
Revenues
4.77b
+15.15%
Net income
-317m
L+21.92%
CFO
232m
P
Earnings
May 29, 2025
Profile
Bausch + Lomb Corporation operates as an eye health company worldwide. It operates through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, and dry eye. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of eye conditions, such as glaucoma, ocular hypertension, and retinal diseases; and contact lenses for therapeutic use. The Surgical segment provides tools and technologies for the treatment of cataracts, and vitreous and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices. The company was founded in 1853 and is headquartered in Vaughan, Canada.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | |||||||
Revenues | 4,774,000 15.15% | 4,146,000 10.03% | 3,768,000 0.08% | ||||
Cost of revenue | 2,233,000 | 3,702,000 | 3,304,000 | ||||
Unusual Expense (Income) | |||||||
NOPBT | 2,541,000 | 444,000 | 464,000 | ||||
NOPBT Margin | 53.23% | 10.71% | 12.31% | ||||
Operating Taxes | 71,000 | 82,000 | 58,000 | ||||
Tax Rate | 2.79% | 18.47% | 12.50% | ||||
NOPAT | 2,470,000 | 362,000 | 406,000 | ||||
Net income | (317,000) 21.92% | (260,000) -1,833.33% | 15,000 -91.76% | ||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | (10,000) | ||||||
BB yield | 0.17% | ||||||
| Debt | |||||||
Debt current | 40,000 | 30,000 | 25,000 | ||||
Long-term debt | 4,744,000 | 4,706,000 | 2,503,000 | ||||
Deferred revenue | |||||||
Other long-term liabilities | 430,000 | 310,000 | 329,000 | ||||
Net debt | 4,479,000 | 4,405,000 | 2,162,000 | ||||
| Cash flow | |||||||
Cash from operating activities | 232,000 | (17,000) | 345,000 | ||||
CAPEX | (291,000) | (181,000) | (175,000) | ||||
Cash from investing activities | (412,000) | (2,109,000) | (215,000) | ||||
Cash from financing activities | 178,000 | 2,078,000 | 81,000 | ||||
FCF | 2,452,000 | (78,000) | 198,000 | ||||
| Balance | |||||||
Cash | 305,000 | 331,000 | 354,000 | ||||
Long term investments | 12,000 | ||||||
Excess cash | 66,300 | 123,700 | 177,600 | ||||
Stockholders' equity | (1,885,000) | (1,429,000) | (1,184,000) | ||||
Invested Capital | 13,643,000 | 13,308,000 | 11,050,000 | ||||
ROIC | 18.33% | 2.97% | 3.91% | ||||
ROCE | 21.59% | 3.73% | 4.70% | ||||
| EV | |||||||
Common stock shares outstanding | 351,800 | 350,500 | 350,000 | ||||
Price | 18.06 5.86% | 17.06 9.99% | 15.51 | ||||
Market cap | 6,353,508 6.25% | 5,979,530 10.15% | 5,428,500 | ||||
EV | 10,903,508 | 10,454,530 | 7,658,500 | ||||
EBITDA | 2,977,000 | 826,000 | 843,000 | ||||
EV/EBITDA | 3.66 | 12.66 | 9.08 | ||||
Interest | 399,000 | 283,000 | 146,000 | ||||
Interest/NOPBT | 15.70% | 63.74% | 31.47% | ||||